课题基金 / 基金详情

Technological Development Component

Technological Development Component
技术开发部分
批准号:
6849599
负责人:
Thomas M Moran
金额:
$163.32万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2009-08-31

项目摘要

项目成果

Thomas M Moran的其他基金

相似基金

相关文献

中文摘要
翻译
人类对感染性病原体的免疫反应的研究因以下几个因素而变得复杂:1)许多微生物产生拮抗蛋白,干扰免疫反应的各个方面;2)免疫反应是通过与多种细胞类型的一系列相互作用产生的,每个病原体与每种类型的相互作用可能不同;3)人类群体的遗传变异。技术发展部门(TDC)通过开发新技术来应对这些问题,这些新技术将全面介绍人类对病毒病原体的反应。尽管很明显,大多数病毒(如果不是所有病毒)都编码与免疫逃避有关的基因产物,但对这些病毒基因对人类免疫反应的影响知之甚少。我们计划建立的检测方法将1)利用表达这种拮抗剂的嵌合I病毒(CV)来鉴定和鉴定病毒免疫功能的抑制剂;2)从三个阶段来描述人类对病毒的免疫反应的诱导:先天免疫、先天适应界面和获得性免疫;通过在I基因转录、干扰素信号转导、细胞因子/细胞表面标志的表达和肽递呈的水平上表征细胞对病毒感染的反应的动力学;3)尝试确定影响免疫反应诱导中的关键基因转录水平的人类基因多态。以新城疫或仙台病毒为骨架构建CV是TDC的一项整体创新,将1)允许安全地研究被认为编码免疫拮抗剂蛋白的单个病原体基因;2)刺激干扰素途径激活和髓系树突状细胞(MDCs)的成熟,从而读出异源拮抗剂活性;50-100个基因的qPCR板将用于研究病毒与相关细胞类型在免疫的三个阶段中的每个阶段的相互作用。小组1(先天免疫)将用于检查先天免疫 干扰素产生的三种主要细胞类型(MDCs、PDCs和上皮细胞)中的基因转录。第2组(先天适应性)将测量成熟期间MDC中激活的基因的上调,第3组(适应性)将评估同种异体MDCS刺激的T细胞中激活的基因。使用来自临床核心和含有拮抗剂的野生型或嵌合病毒的样本,我们将生成人类对病毒的反应概况,并绘制拮抗剂的影响图。患者样本将通过一种简单的等位基因不平衡分析进一步测试关键免疫候选基因的基因转录变异。收集的数据将与患者的病史相关联,并应有助于识别 易受特定病毒感染的改变个体的亚群。贸发局开发的技术将与该中心的其他调查人员积极合作,以识别和研究病毒拮抗剂。人类对病毒的细胞免疫反应和病毒拮抗剂的影响将在我们的数据库中汇编和分析。
英文摘要
Studies of human immune responses to infectious agents are complicated by several factors: 1) many microbes produce antagonistic proteins that interfere with various aspects of the immune response; 2) immune responses are generated through a series of interactions with multiple cell types and individual pathogens may interact differently with each type; 3) genetic variation in the human population. The Technology Development Component (TDC) confronts these issues through the development of novel technologies that will provide a comprehensive profile of human responses to viral pathogens. Although it has become apparent that most if not all viruses encode gene products implicated in evasion of immunity, very little is known on the impact of these viral genes on the human immune response. We are planning to establish assays that will 1) identify and characterize viral inhibitors of immune function using chimeric I viruses (CV) expressing such antagonists; 2) generate a molecular depiction of the induction of the human immune response against viruses at three stages: innate immunity, the innate-adaptive interface and adaptive immunity; by characterizing the kinetics of the cellular response to viral infection at the levels of I gene transcription, IFN signaling, cytokine/cell surface marker expression and peptide presentation; 3) attempt to identify human gene polymorphisms that impact the levels of transcription of critical genes involved in the induction of the immune response. The construction of CV using Newcastles disease or Sendai virus as a backbone is an integral innovation of the TDC, and will 1) allow safe investigation of individual pathogens genes thought to code for immune antagonist proteins; 2) stimulate interferon pathway activation and maturation of myeloid dendritic cells (mDCs) allowing a readout of heterologous antagonist activity, qPCR panels of 50-100 genes will be used to investigate the interactions of viruses and pertinent cell types at each of the three stages of immunity. Panel 1 (innate) will be used to examine innate immune gene transcription in the three major interferon producing cell types (mDCs, pDCs and epithelial cells). Panel 2 (innate-adaptive) will measure upregulation of genes activated in mDC during maturation and panel 3 (adaptive) will evaluate genes activated in T cells stimulated with allogeneic mDCs. Using samples from the clinical core and wild type or chimeric viruses containing antagonists, we will generate profiles of human responses to viruses and the map the impact of the antagonists. Patient samples will be further tested for genetically determined transcription variation in key immune candidate genes by a simple allelic imbalance assay. This data collected will be correlated with patient medical history and should assist in identification of subgroups of individuals with altered susceptible to specific virus infections. The technology developed by the TDC will be used in active collaboration with the other investigators in the center to identify and investigate viral antagonists. The human cellular immune response profiles to viruses and the impact of viral antagonists will be compiled and analyzed in our database.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Center for Investigating Viral Immunity and Antagonism
Inflammatory Response in Influenza Virus Infection
Inflammatory Response in Influenza Virus Infection
Inflammatory Dendritic Cells in Influenza Virus Infection
海外基金